Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

First UK Guidelines For Kidney Cancer Recommend Pfizer's Sutent(R) (sunitinib) As A First-line Treatment For Metastatic Renal Cell Carcinoma
Today Sutent® (sunitinib) has received a recommendation as a
generic viagra online
Norovirus And Salmonella Were Leading Causes Of Foodborne Disease Outbreaks In 2006
Norovirus and Salmonella were the leading causes of foodborne disease outbreaks in 2006, according to a report released by the Centers for Disease Control and Prevention. The report, based on investigations of foodborne disease outbreaks provides the most recent report of how many illnesses were linked to specific types of foods.
News of the day
Could Hormones Explain Gender Differences In Neurological Disease?
Neurological diseases including Parkinson"s, Tourette"s, attention deficit hyperactivity disorder (ADHD), Alzheimer"s, and schizophrenia are all associated with alterations in dopamine-driven function involving the dopamine transporter (DAT). Research published recently in the open access journal BMC Neuroscience suggests that a number of estrogens acting through their receptors affect the DAT, which may explain trends in timing of women"s susceptibility to these diseases.
Mental Health

Advaxis Engages The Numoda Corporation To Oversee Phase II Clinical Trials Of ADXS11-001

Advaxis, Incorporated (OTCBB: ADXS), has engaged the Numoda Corporation, a leading clinical trial and logistics management company, to oversee Phase II clinical activity with ADXS11-001 for the treatment of invasive cervix cancer and cervical intraepithelial neoplasia (CIN; cervical dysplasia). Numoda will integrate oversight and logistical functions with the clinical research organizations (CRO), contract laboratories, academic laboratories and statistical groups involved. "The Numoda Corporation offers experience and res that will enable Advaxis to execute multiple high quality clinical trials with precision, efficiency, high quality data and a rapid final study report," commented Advaxis EVP of Science and Operations Dr. John Rothman. Advaxis anticipates that the Numoda Corporation"s involvement will help expedite the clinical trial process. The Company anticipates initiating trial activity in September 2009 as described and delineated in the Company"s most recent 10-Q filing. For more information on public filing documents, please visit the US Security and Exchange Commission"s website at: http://www.sec.gov. Numoda Corporation Advaxis, Incorporated


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009